Looking for a substitute for Mounjaro KwikPen in India? Yurpeak KwikPen is an alternative brand of tirzepatide marketed and distributed by Cipla under an agreement with Eli Lilly. Both Mounjaro and Yurpeak contain tirzepatide, making Yurpeak a relevant option to discuss with a qualified healthcare professional when considering treatment alternatives.
Yurpeak KwikPen: An Alternative to Mounjaro KwikPen
Eli Lilly and Company launched Mounjaro in India in March 2025. In October 2025, Lilly announced an agreement with Cipla Limited to distribute and promote tirzepatide in India under the brand name Yurpeak. Lilly manufactures and supplies Yurpeak, while Cipla handles its promotion and distribution in India.
This agreement does not mean that Cipla received the rights to market Mounjaro under the same brand name. Instead, Yurpeak is a separate brand of Lilly’s tirzepatide. This distinction is important for buyers and patients searching for a substitute for Mounjaro KwikPen.
What Is Yurpeak KwikPen?
Yurpeak KwikPen is a prescription-based, prefilled injection pen containing tirzepatide. Tirzepatide acts on GIP and GLP-1 receptors and is prescribed, where approved, alongside diet and exercise for type 2 diabetes management and chronic weight management in eligible adults.
Yurpeak KwikPen is available in multiple strengths, including 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg. The appropriate strength and treatment schedule must be determined by a qualified healthcare professional.
Mounjaro KwikPen vs Yurpeak KwikPen
The principal similarity between these products is their active ingredient: tirzepatide. Their brand names and commercial distribution arrangements differ.
Mounjaro KwikPen: The original Lilly brand of tirzepatide.
Yurpeak KwikPen: A second Lilly tirzepatide brand promoted and distributed by Cipla in India under a commercial agreement.
Active ingredient: Tirzepatide in both brands.
Administration: Prescription-based, once-weekly injection, according to the approved product instructions.
Strengths: Multiple strengths are available for individualised treatment under medical supervision.
Although both contain tirzepatide, patients should not change brands, strengths or dosing schedules without consulting their prescribing clinician and confirming the product’s approved instructions.
Where Can Buyers Find Yurpeak KwikPen?
Patients should obtain prescription medicines through licensed pharmacies and authorised distribution channels. Buyers and healthcare professionals should verify product authenticity, availability, storage requirements and applicable prescription regulations before purchasing.
For international pharmaceutical procurement, the brand’s availability and marketing authorisation may differ by country. Yurpeak’s Indian distribution agreement should not be interpreted as automatic authorisation to sell the product in other markets.
About Cordium Pharmaceuticals Pvt Ltd
Cordium Pharmaceuticals Pvt Ltd is an India-based pharmaceutical supplier and exporter serving international pharmaceutical sourcing requirements. Buyers seeking information about pharmaceutical products, export documentation and applicable market requirements can contact the company to discuss their procurement needs.
Any supply of tirzepatide products must be subject to the relevant manufacturer or marketing authorisation holder’s permissions, local regulatory approvals and applicable distribution requirements. Cordium Pharmaceuticals Pvt Ltd should not be understood to be an authorised supplier of Mounjaro or Yurpeak unless such authorisation has been independently confirmed.
Frequently Asked Questions
1. What is the substitute for Mounjaro KwikPen in India?
Yurpeak KwikPen is a second brand of tirzepatide introduced in India through an agreement between Eli Lilly and Cipla. Ask your healthcare professional whether it is appropriate for your treatment.
2. Has Lilly given Cipla the marketing rights for Mounjaro?
Lilly and Cipla announced a distribution and promotion agreement for Yurpeak, not a transfer of the Mounjaro brand. Lilly continues to manufacture and supply Yurpeak, while Cipla promotes and distributes it in India.
3. Do Mounjaro and Yurpeak contain the same ingredient?
Yes. Both brands contain tirzepatide. However, patients should confirm the product presentation, strength and approved instructions before any treatment change.
4. Can I switch from Mounjaro to Yurpeak myself?
No. Consult your prescribing healthcare professional before changing brands, doses or treatment schedules.
5. Can Yurpeak be exported from India?
Export eligibility depends on applicable regulations, marketing authorisations and the rights granted by the manufacturer or marketing authorisation holder. Buyers should verify these requirements for the destination country before placing an order.
Yurpeak KwikPen: An Alternative to Mounjaro KwikPen
Eli Lilly and Company launched Mounjaro in India in March 2025. In October 2025, Lilly announced an agreement with Cipla Limited to distribute and promote tirzepatide in India under the brand name Yurpeak. Lilly manufactures and supplies Yurpeak, while Cipla handles its promotion and distribution in India.
This agreement does not mean that Cipla received the rights to market Mounjaro under the same brand name. Instead, Yurpeak is a separate brand of Lilly’s tirzepatide. This distinction is important for buyers and patients searching for a substitute for Mounjaro KwikPen.
What Is Yurpeak KwikPen?
Yurpeak KwikPen is a prescription-based, prefilled injection pen containing tirzepatide. Tirzepatide acts on GIP and GLP-1 receptors and is prescribed, where approved, alongside diet and exercise for type 2 diabetes management and chronic weight management in eligible adults.
Yurpeak KwikPen is available in multiple strengths, including 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg. The appropriate strength and treatment schedule must be determined by a qualified healthcare professional.
Mounjaro KwikPen vs Yurpeak KwikPen
The principal similarity between these products is their active ingredient: tirzepatide. Their brand names and commercial distribution arrangements differ.
Mounjaro KwikPen: The original Lilly brand of tirzepatide.
Yurpeak KwikPen: A second Lilly tirzepatide brand promoted and distributed by Cipla in India under a commercial agreement.
Active ingredient: Tirzepatide in both brands.
Administration: Prescription-based, once-weekly injection, according to the approved product instructions.
Strengths: Multiple strengths are available for individualised treatment under medical supervision.
Although both contain tirzepatide, patients should not change brands, strengths or dosing schedules without consulting their prescribing clinician and confirming the product’s approved instructions.
Where Can Buyers Find Yurpeak KwikPen?
Patients should obtain prescription medicines through licensed pharmacies and authorised distribution channels. Buyers and healthcare professionals should verify product authenticity, availability, storage requirements and applicable prescription regulations before purchasing.
For international pharmaceutical procurement, the brand’s availability and marketing authorisation may differ by country. Yurpeak’s Indian distribution agreement should not be interpreted as automatic authorisation to sell the product in other markets.
About Cordium Pharmaceuticals Pvt Ltd
Cordium Pharmaceuticals Pvt Ltd is an India-based pharmaceutical supplier and exporter serving international pharmaceutical sourcing requirements. Buyers seeking information about pharmaceutical products, export documentation and applicable market requirements can contact the company to discuss their procurement needs.
Any supply of tirzepatide products must be subject to the relevant manufacturer or marketing authorisation holder’s permissions, local regulatory approvals and applicable distribution requirements. Cordium Pharmaceuticals Pvt Ltd should not be understood to be an authorised supplier of Mounjaro or Yurpeak unless such authorisation has been independently confirmed.
Frequently Asked Questions
1. What is the substitute for Mounjaro KwikPen in India?
Yurpeak KwikPen is a second brand of tirzepatide introduced in India through an agreement between Eli Lilly and Cipla. Ask your healthcare professional whether it is appropriate for your treatment.
2. Has Lilly given Cipla the marketing rights for Mounjaro?
Lilly and Cipla announced a distribution and promotion agreement for Yurpeak, not a transfer of the Mounjaro brand. Lilly continues to manufacture and supply Yurpeak, while Cipla promotes and distributes it in India.
3. Do Mounjaro and Yurpeak contain the same ingredient?
Yes. Both brands contain tirzepatide. However, patients should confirm the product presentation, strength and approved instructions before any treatment change.
4. Can I switch from Mounjaro to Yurpeak myself?
No. Consult your prescribing healthcare professional before changing brands, doses or treatment schedules.
5. Can Yurpeak be exported from India?
Export eligibility depends on applicable regulations, marketing authorisations and the rights granted by the manufacturer or marketing authorisation holder. Buyers should verify these requirements for the destination country before placing an order.
Keywords
